GBS Infection Statistics in Mothers and Infants
Among GBS-colonized pregnant women, approximately 10-30% carry the organism, and without intrapartum antibiotic prophylaxis, about 1-2% of their infants will develop early-onset invasive GBS disease. 1, 2
Maternal GBS Colonization Rates
The prevalence of maternal GBS colonization varies but is consistently documented across multiple guidelines:
- 17-22% of pregnant women are colonized with GBS in the vagina or rectum 1, 2, 3, 4
- Recent large cohort data shows colonization rates of 21.6% in modern populations 4
- A 2024 meta-analysis of 355,787 matched mother-infant pairs found a pooled maternal colonization prevalence of 17.1% 3
Vertical Transmission Statistics
The risk of mother-to-infant transmission is substantial but variable:
- Without prophylaxis, approximately 51% of infants born to colonized mothers become colonized themselves 5
- With intrapartum antibiotic prophylaxis, neonatal colonization drops dramatically to 9% 5
- The pooled vertical transmission rate is 4.5% when measuring actual GBS colonization in neonates 3
- Neonates born to GBS-positive mothers have 9.9 times the risk of GBS colonization compared to those born to GBS-negative mothers 3
Infant Infection Rates
Without Prophylaxis
The risk of early-onset invasive disease varies dramatically based on risk factors:
- GBS-colonized women WITHOUT risk factors: 5.1 cases per 1,000 births 1
- GBS-colonized women WITH risk factors (preterm labor, prolonged membrane rupture >12 hours, or intrapartum fever): The risk is 8-fold higher than colonized women without risk factors and 45-fold higher than women with risk factors who are not colonized 5
- In one controlled trial, 6% of infants (approximately 1 in 17) born to high-risk colonized mothers without prophylaxis developed early-onset invasive disease 5
With Intrapartum Antibiotic Prophylaxis
Intrapartum antibiotic prophylaxis is highly effective:
- Early trials suggested 100% efficacy in preventing early-onset disease 1
- Subsequent observational studies demonstrate 86-89% effectiveness in real-world settings 1
- A meta-analysis estimated a 30-fold reduction in early-onset GBS disease with intrapartum chemoprophylaxis 5
- In the landmark randomized controlled trial, 0% of infants in the treatment group developed early-onset disease compared to 6% in controls 5
Current Disease Burden
In the modern era with universal screening and prophylaxis:
- Overall early-onset GBS disease incidence: 0.25-0.67 per 1,000 live births in Europe and the Americas 6
- In the UK: approximately 0.9 per 1,000 live births 7
- Recent data shows NICU admission rates of 8.3% and culture-positive neonatal sepsis in 1.1% of infants born to GBS-positive mothers receiving prophylaxis 8
- The case-fatality ratio for early-onset disease is approximately 4-6% 2, 7
High-Risk Populations
Certain maternal factors significantly increase infection risk:
- Women with GBS bacteriuria during pregnancy have particularly high risk, with up to 61% experiencing miscarriage or stillbirth 6
- High-density GBS colonization increases adverse outcomes: neonatal infection rates of 14.16% vs. 6.89% in low-density colonization 9
- Women with risk factors (fever, prolonged rupture of membranes >18 hours, delivery <37 weeks) but negative screening cultures have relatively low risk: 0.9 cases per 1,000 births 1
Maternal Outcomes
GBS colonization affects maternal health as well:
- Postpartum maternal febrile illness is significantly reduced with intrapartum prophylaxis 5
- High GBS colonization increases puerperal infection rates (23% vs. 14%), premature rupture of membranes (35% vs. 19%), and postpartum hemorrhage (19% vs. 9%) 9
Important Caveats
The effectiveness of prophylaxis depends critically on timing: antibiotics must be administered ≥4 hours before delivery for optimal protection, though durations ≥2 hours may confer some benefit 1. Despite widespread implementation of screening and prophylaxis protocols resulting in an estimated 80% reduction in early-onset GBS disease 10, GBS remains the leading cause of early-onset neonatal sepsis in developed countries 10, 7.